BIIB consolidation might get to end and a new move up possible.

NASDAQ:BIIB   Biogen Inc
BIIB shares might the consolidation channel and prepare a move higher.
The reason would be that the market discounts the potential sales CAGR for Alzheimer's drugs, reimbursements being an issue.
If the problem gets solved, BIIB gets a clear path towards higher valuation.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.